MyFinsight
Home
Blog
About
Kailera Therapeutics, Inc. (KLRA)
Kailera Therapeutics, Inc. (KLRA)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Maturities of marketable securit...
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Payments of deferred offering co...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
Net loss
-111,307
-78,865
Depreciation and amortization expense
101
101
Stock-based compensation expense
8,344
3,939
Change in fair value of preferred stock tranche right liability
0
0
Non-cash lease expense
-272
-293
Accretion of discounts on investments, net
1,667
1,225
Change in fair value of convertible promissory notes
0
-
Other
-8
19
Prepaid expenses and other current assets
1,285
-42
Non-current clinical deposits
1,353
1,133
Other non-current assets
-2,289
-27
Accounts payable
12,338
-495
Accrued expenses and other current liabilities
15,054
9,376
Operating lease liabilities
-255
-282
Other non-current liabilities
-66
-69
Net cash used in operating activities
-77,527
-68,310
Purchases of marketable securities
689,811
48,448
Maturities of marketable securities
118,787
71,297
Net cash used in investing activities
-571,024
22,849
Proceeds from the exercise of stock options
430
57
Proceeds from issuance of convertible promissory notes
0
-
Proceeds from issuance of common stock, net of commissions and underwriting discounts
668,438
-
Payments of deferred offering costs related to initial public offering
1,842
3,037
Net cash provided by financing activities
667,026
-2,980
Net decrease in cash, cash equivalents and restricted cash
18,475
-48,441
Cash, cash equivalents and restricted cash at beginning of period
112,587
161,028
Cash, cash equivalents and restricted cash at end of period
131,062
112,587
Cash and cash equivalents
130,301
-
Restricted cash
761
-
Total cash, cash equivalents and restricted cash
131,062
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, net of...
$668,438K
Proceeds from the
exercise of stock options
$430K
Net cash provided by
financing activities
$667,026K
Canceled cashflow
$1,842K
Net decrease in
cash, cash...
$18,475K
Canceled cashflow
$648,551K
Payments of deferred
offering costs related to...
$1,842K
Maturities of marketable
securities
$118,787K
Accrued expenses and
other current...
$15,054K
Accounts payable
$12,338K
Stock-based compensation
expense
$8,344K
Other non-current
assets
-$2,289K
Non-cash lease expense
-$272K
Depreciation and
amortization expense
$101K
Other
-$8K
Net cash used in
investing activities
-$571,024K
Net cash used in
operating activities
-$77,527K
Canceled cashflow
$118,787K
Canceled cashflow
$38,406K
Purchases of marketable
securities
$689,811K
Net loss
-$111,307K
Accretion of discounts on
investments, net
$1,667K
Non-current clinical
deposits
$1,353K
Prepaid expenses and
other current assets
$1,285K
Operating lease
liabilities
-$255K
Other non-current
liabilities
-$66K
Buy us a coffee